Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines

Journal of Orthopaedic Surgery and Research

Ren-rong Gong²  Hong Duan¹  Yan Xiong¹  Xiao-rong Yang² 

[1] Department of Orthopedics, West China Hospital, Sichuan University, No 37, Guo Xue Lane, Chengdu 610041, Sichuan, People’s Republic of China;Department of Operation Room, West China Hospital, Sichuan University, No 37, Guo Xue Lane, Chengdu 610041, Sichuan, People’s Republic of China

关键词: Microarray data;    Methotrexate resistance;    Osteosarcoma;   

Others  :  1227823
DOI  :  10.1186/s13018-015-0275-8

 received in 2015-06-05, accepted in 2015-08-09,  发布年份 2015

【 摘 要 】

Background

This study aimed to better understand the mechanisms underlying methotrexate (MTX)—resistance in osteosarcoma.

Methods

The raw transcription microarray data GSE16089 collected from three MTX-sensitive osteosarcoma (Saos-2) cell samples and three MTX-resistant osteosarcoma (Saos-2) cell samples were downloaded from Gene Expression Omnibus. After data processing, the differentially expressed genes (DEGs) were identified. Next, DEGs were submitted to DAVID for functional annotation based on the GO (Gene Ontology) database, as well as pathway enrichment analysis based on the KEGG (Kyoto Encyclopedia of Genes and Genomes) database. Transcription factors (TFs) and tumor-associated genes (TAGs) were identified with reference to TRANSFAC and TAG, and TSGene databases, respectively. The protein-protein interaction (PPI) network of the gene-encoded products was constructed, and the subnetwork with the highest score was also detected using Search Tool for the Retrieval of Interacting Genes and BioNet package.

Results

A total of 690 up-regulated genes and down-regulated 626 genes were identified. Up-regulated DEGs (including AARS and PARS2) were associated to transfer RNA (tRNA) aminoacylation while down-regulated DEGs (including AURKA, CCNB1, CCNE2, CDK1, and CENPA) were correlated with mitotic cell cycle. Totally, 13 TFs (including HMGB2), 13 oncogenes (including CCNA2 and AURKA), and 19 tumor suppressor genes (TSGs) (including CDKN2C) were identified from the down-regulated DEGs. Ten DEGs, including nine down-regulated genes (such as AURKA, CDK1, CCNE2, and CENPA) and one up-regulated gene (GADD45A), were involved in the highest score subnetwork.

Conclusion

AARS, AURKA, AURKB, CENPA, CCNB1, CCNE2, and CDK may contribute to MTX resistance via aminoacyl-tRNA biosynthesis pathway, cell cycle pathway, or p53 signaling pathway.

【 授权许可】

   
2015 Yang et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Longo-Sorbello G. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica. 2001; 86(2):121-7.
• [2]Kunz P, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Machado I et al. Improved survival in osteosarcoma patients with atypical low vascularization. Annals Surg Oncol. 2015;22(2):489-96.
• [3]Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C et al.. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013; 45(7):799-803.
• [4]Rainusso N, Kurenbekova L, Donehower L, Rosen J, Yustein J. Abstract C80: characterization of metastatic cancer stem cells in osteosarcoma. Cancer Res. 2013; 73(3 Supplement):C80-C.
• [5]Zheng S-e, Xiong S, Lin F, G-l Q, Feng T, Shen Z et al.. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 2012; 33(6):832-8.
• [6]Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR et al.. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999; 5(3):621-7.
• [7]Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P et al.. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995; 87(16):1254-6.
• [8]Yeager TR, Reznikoff CA. Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol. 1998; 159(2):581-5.
• [9]Selga E, Oleaga C, Ramírez S, de Almagro MC, Noé V. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med. 2009; 1(9):83. BioMed Central Full Text
• [10]D’Eustachio P. Reactome knowledgebase of human biological pathways and processes. Bioinformatics for Comparative Proteomics. Springer; 2011;694:49–61.
• [11]Navab R, Strumpf D, Bandarchi B, Zhu C-Q, Pintilie M, Ramnarine VR et al.. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci. 2011; 108(17):7160-5.
• [12]Selga E, Noé V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol. 2008; 75(2):414-26.
• [13]Irizarry RA, Hobbs B, Collin F, Beazer‐Barclay YD, Antonellis KJ, Scherf U et al.. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64.
• [14]Alibes A, Yankilevich P, Canada A, Diaz-Uriarte R. IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics. 2007; 8:9. BioMed Central Full Text
• [15]Consortium GO. The gene ontology (GO) project in 2006. Nucleic Acids Res. 2006; 34(suppl 1):D322-6.
• [16]Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000; 28(1):27-30.
• [17]Heinemeyer T, Chen X, Karas H, Kel AE, Kel O, Liebich I et al.. Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms. Nucleic Acids Res. 1999; 27(1):318-22.
• [18]Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res. 2013; 41(D1):D970-6.
• [19]Von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Krüger B et al.. STRING 7—recent developments in the integration and prediction of protein interactions. Nucleic Acids Res. 2007; 35(suppl 1):D358-62.
• [20]Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al.. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504.
• [21]Beisser D, Klau GW, Dandekar T, Müller T, Dittrich MT. BioNet: an R-Package for the functional analysis of biological networks. Bioinformatics. 2010; 26(8):1129-30.
• [22]Park SG, Ewalt KL, Kim S. Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci. 2005; 30(10):569-74.
• [23]Kim D, Kwon NH, Kim S. Association of aminoacyl-tRNA synthetases with cancer. 2013.
• [24]Williams TF, Mirando AC, Wilkinson B, Francklyn CS, Lounsbury KM. Secreted threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis. Scientific Reports. 2013;3.
• [25]Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control. 2006; 17(1):81-3.
• [26]Saskova A, Solc P, Baran V, Kubelka M, Schultz RM, Motlik J. Aurora kinase A controls meiosis I progression in mouse oocytes. Cell Cycle. 2008; 7(15):2368-76.
• [27]Kunitoku N, Sasayama T, Marumoto T, Zhang D, Honda S, Kobayashi O et al.. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cell. 2003; 5(6):853-64.
• [28]Marumoto T, Zhang D, Saya H. Aurora-A—a guardian of poles. Nat Rev Cancer. 2005; 5(1):42-50.
• [29]Jiang Z, Jiang J, Yang H, Ge Z, Wang Q, Zhang L et al.. Silencing of Aurora kinase A by RNA interference inhibits tumor growth in human osteosarcoma cells by inducing apoptosis and G2/M cell cycle arrest. Oncol Rep. 2014; 31(3):1249-54.
• [30]Gu X-M, Fu J, Feng X-J, Huang X, Wang S-M, Chen X-F et al.. Expression and prognostic relevance of centromere protein A in primary osteosarcoma. Pathol Res Pract. 2014; 210(4):228-33.
• [31]Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012; 226(2):352-64.
• [32]Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411(6835):342-8.
• [33]Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66.
• [34]Han X-R, Sun Y, Bai X-Z. The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells. Cell Signal. 2012; 24(8):1713-21.
• [35]Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J et al.. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther. 2011; 10(6):1018-27.
• [36]Uchiyama H, Sowa Y, Wakada M, Yogosawa M, Nakanishi R, Horinaka M et al.. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells. Cancer Sci. 2010; 101(3):728-34.
• [37]Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB et al.. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011; 306(2):161-70.